Xilio Therapeutics, Inc.
- Market cap
- $56.87M
- 52w range
- $6.47 - $12.59
- Sector
- Healthcare
- Data quality
- 83/100
- fair value estimate
- $7.79
- Margin of safety
- -12.6%
- Moat score
- 41/100
- Return on equity
- -75.2%
- Profit margin
- -58.5%
- Debt / equity
- 0.09
- Revenue growth
- +331.7%
- Analyst target
- $20.00
- Target upside
- +124.5%
- Analysts
- 1
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Valuation
Derived from filed metrics · High confidence (83% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).